Key result
Dexmedetomidine infusion (0.5 mcg/kg/h) significantly reduced the incidence of hypertension and tachycardia during awakening compared to placebo after transsphenoidal resection of pituitary adenoma.
Why the study?
Optimizing anesthesia during transsphenoidal surgery requires preventing hypertension and agitation during emergence, and adding dexmedetomidine as an adjuvant could address these clinical challenges.
Does dexmedetomidine infusion prevent hypertension and agitation during awakening in adult patients with pituitary microadenoma and baseline hypertension undergoing transsphenoidal resection?
RCT (n=40)
Does dexmedetomidine infusion prevent hypertension and agitation during awakening in adult patients with pituitary microadenoma and baseline hypertension undergoing transsphenoidal resection?
Dexmedetomidine infusion during transsphenoidal resection of pituitary adenomas reduces postoperative hypertension, tachycardia, and agitation during awakening.
May support dexmedetomidine for emergence hemodynamic control after transsphenoidal surgery; hypothesis-generating and requires RCT confirmation in baseline hypertension.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Arefiev et al. (2020) conducted an RCT in Pituitary microadenoma with baseline hypertension (n=40). Dexmedetomidine vs. Placebo (0.9% NaCl) was evaluated on Incidence of hypertension and tachycardia during awakening. Dexmedetomidine infusion (0.5 mcg/kg/h) significantly reduced the incidence of hypertension and tachycardia during awakening compared to placebo after transsphenoidal resection of pituitary adenoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: